Expertise in
5
conditions

Artur Jurczyszyn

Krakow, MA, PL 
Expertise in
5
conditions
Krakow, MA, PL 

Overview

Artur Jurczyszyn practices practicing medicine in Krakow, Poland.

Mr. Jurczyszyn is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Plasmacytoma, POEMS Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 172 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Krakow, MA, Poland
Other Locations
31155, Poland
Wroclaw, DS, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 3
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
View 2 Less Clinical Trials

172 Total Publications

Correction: CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.
Correction: CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.
Journal: Molecular cancer
Published: July 17, 2026

Frequently Asked Questions about Artur Jurczyszyn

Is Artur Jurczyszyn a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Artur Jurczyszyn is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Artur Jurczyszyn participate in research or clinical trials?

Yes. Artur Jurczyszyn has published 172 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Artur Jurczyszyn's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Jurczyszyn's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile